ERBB2 and breast cancer: Given the clinical relevance of tumors with HER2 IHC3+ expression, we further evaluated the prevalence of HER2 IHC overexpression (1+, 2+, and 3+), using ASCO/CAP breast cancer guidelines for breast cancer specimens and ASCO/CAP gastric cancer scoring criteria for non-breast cancers.